Aronora’s unique product candidates address the unmet medical need for safe and early field treatment and prevention of cardio-vascular emergencies, including stroke, heart attack, and severe infection associated bleeding due to consumptive coagulopathy (disseminated intravascular coagulation, DIC). Our products are intended for use when antithrombotic therapy could result in survival and other critical outcome benefits, but current antithrombotic drugs on the market pose too high a risk of bleeding and are therefore not used.
Blood clots cause more deaths and disability than all other diseases combined. Despite medical advances, there are no safe drugs that could interrupt pathological blood clotting (thrombosis) without the risk of fatal bleeding. Due to this risk, virtually none of the existing antithrombotic drugs are used in thrombotic medical emergencies or in patients with increased risk of bleeding.
Blood clots in arteries and veins (thrombosis) can cause stroke, heart attack, pulmonary embolism, and other medical emergencies that must be treated immediately to reduce further organ damage. Yet, in the absence of a safe antithrombotic treatment, the deadliest cardiovascular emergencies almost never get treated with antithrombotic agents in time. Most emergency treatments are palliative. Causal treatment approaches require rapid transportation of the victim to a capable medical facility where such treatments can be delivered, if at all, more safely.